Ocrevus (ocrelizumab)

This study provides insight into unique biomarker profile in patients on ocrelizumab. Increased BAFF was associated with lower IgG and IgA levels, biomarkers of neuroaxonal damage and inflammation in MS patients without recent acute inflammatory activity on ocrelizumab.

P=N/A, N=111, Not yet recruiting, Region Stockholm | Initiation date: Oct 2025 --> Feb 2026

P=N/A, N=800, Completed, Brigham and Women's Hospital | Not yet recruiting --> Completed | N=600 --> 800

P=N/A, N=842, Recruiting, Hoffmann-La Roche | N=349 --> 842 | Trial completion date: Nov 2026 --> Mar 2028 | Trial primary completion date: Nov 2026 --> Mar 2028

P2, N=182, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting

P3, N=1055, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed

P3, N=175, Recruiting, Sandoz | N=518 --> 175 | Trial primary completion date: May 2027 --> Oct 2026

P=N/A, N=100, Not yet recruiting, Northwestern University

P3, N=250, Not yet recruiting, University Hospital, Montpellier

P=N/A, N=134, Completed, Novartis Pharmaceuticals | Recruiting --> Completed | N=100 --> 134

She received five days of high-dose intravenous methylprednisolone, leading to significant improvement in her gait, and was started on ocrelizumab infusions on post-hospital discharge follow-up. Future research is warranted to determine whether patients with NF1 harbor an intrinsic predisposition to autoimmune CNS disorders such as MS, and whether neurofibromin deficiency plays a role in immune dysregulation. Ultimately, this case calls for a high index of clinical suspicion, multidisciplinary collaboration, and judicious use of advanced diagnostics in managing patients with complex neurological disorders.

P3, N=769, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Mar 2029 --> Sep 2027